# Tina Cascone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tina-cascone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,217 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 54 |
| i10-index | 122 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5062198066 |
| ORCID iD | 0000-0003-3008-5407 |
| Works | 452 |

## Researcher papers

- [Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy](https://scholariq.org/papers/loss-of-pten-promotes-resistance-to-t-cell-mediated-immunotherapy/)
- [Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy](https://scholariq.org/papers/increased-tumor-glycolysis-characterizes-immune-resistance-to-adoptive-t-cell/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Perioperative Nivolumab in Resectable Lung Cancer](https://scholariq.org/papers/perioperative-nivolumab-in-resectable-lung-cancer/)
- [CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade](https://scholariq.org/papers/cd38-mediated-immunosuppression-as-a-mechanism-of-tumor-cell-escape-from-pd-1-pd/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy](https://scholariq.org/papers/molecular-mechanisms-and-future-implications-of-vegf-vegfr-in-cancer-therapy/)
- [Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer](https://scholariq.org/papers/evolution-of-systemic-therapy-for-stages-i-iii-non-metastatic-non-small-cell/)
- [An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition](https://scholariq.org/papers/an-integrin-3-kras-ralb-complex-drives-tumour-stemness-and-resistance-to-egfr/)
- [Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance](https://scholariq.org/papers/combined-vascular-endothelial-growth-factor-receptor-and-epidermal-growth-factor/)
- [Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i> -Mutant Transformed Small Cell Lung Cancer](https://scholariq.org/papers/multi-institution-analysis-of-tarlatamab-for-the-treatment-of-i-egfr-i-mutant/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.